Implantica to Present Q3 2025 Financial Results on October 31, 2025
Implantica to Present Q3 2025 Financial Results
Implantica AG, a notable medtech firm based in Vaduz, Liechtenstein, is gearing up to present its financial results for the third quarter of 2025. This significant event is scheduled to take place on October 31, 2025, at 3:00 PM CET. Investors and stakeholders will have the opportunity to tune into a detailed presentation, focusing on the company's performance and strategic direction moving forward.
Event Details
The interim financial report for the third quarter will be made publicly available at 8:00 AM CET earlier on the same day, allowing for a comprehensive overview before the presentation. The presentation will be conducted in English and accessible via a webcast. Investors wishing to join the online event can do so by following a provided link: Webcast Link.
For those preferring to participate via teleconference, registration is required. Upon registering, participants will receive the phone number and unique conference ID to join the call. The registration for this option can be found here: Teleconference Registration.
Speaking at the Event
The presentation will feature prominent speakers from within Implantica. CEO Peter Forsell, CFO Andreas Öhrnberg, and Chief Corporate Affairs Officer Nicole Pehrsson will provide insights into the company's developments, variations in financial metrics, and strategies aimed at enhancing shareholder value.
About Implantica
Implantica is known for its revolutionary approach in the medtech sector, primarily focusing on integrating advanced technologies into medical devices. Their flagship product, RefluxStop™, is a CE-marked implant designed to prevent gastroesophageal reflux, promising to induce a change in how anti-reflux treatments are administered. This product's success in clinical trials has strengthened the company's position in the healthcare market.
Additionally, Implantica is innovating in the field of eHealth by developing a sophisticated range of technologies. This includes a patented eHealth platform designed for remote patient monitoring and treatment control, as well as a wireless energy platform aimed at powering implants without invasive procedures.
Implantica’s stock is listed on the Nasdaq First North Premier Growth Market under the ticker symbol IMP A SDB. The company’s operations navigate towards a bright future in medical technology, with ongoing enhancements to improve patient care and outcomes.
Investor Relations Contact
For further inquiries regarding the Q3 presentation or general investor relations, you can contact Nicole Pehrsson at +41 43 505 20 57 or via email at [email protected]
Stay updated on Implantica’s latest advancements and insights by visiting their official website: Implantica Official Website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.